IL2 and metastatic melanoma: The first cytokine therapy, interleukin-2 (IL-2, aldesleukin), was approved by the U.S. FDA in 1992 for the treatment of metastatic renal cellcarcinoma and later in 1998 for metastatic melanoma (3).